Patupilone

DRUG13 trials

Sponsors

Novartis Pharmaceuticals, British Columbia Cancer Agency, University of Medicine and Dentistry of New Jersey, University of Zurich

Conditions

Advanced MalignanciesAdvanced Solid TumorsBrain MetastasisCarcinoma, Non-Small-Cell LungHepatocellular CarcinomaHormone Refractory Prostate CancerMetastatic Hormone Refractory Prostate CancerNon-small Cell Lung Cancer

Phase 1

Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

CompletedNCT00171834

Novartis PharmaceuticalsCarcinoma, Non-Small-Cell Lung

Start: 2003-08-31End: 2008-09-30Updated: 2014-02-05

Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan

CompletedNCT00412789

Novartis PharmaceuticalsTumors

Start: 2006-08-31Updated: 2010-05-31

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

CompletedNCT00426140

Novartis PharmaceuticalsAdvanced Malignancies, Solid Tumors

Start: 2006-08-31Updated: 2020-12-08

Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

CompletedNCT00426582

Novartis PharmaceuticalsAdvanced Solid Tumors

Start: 2006-08-31Updated: 2020-12-09

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)

WithdrawnNCT00442741

Novartis PharmaceuticalsSolid Tumors

Start: 2007-07-31Updated: 2012-04-25

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

CompletedNCT00448396

Novartis PharmaceuticalsAdvanced Malignancies

Start: 2007-03-31Updated: 2009-11-19

The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

TerminatedNCT00468260

Novartis PharmaceuticalsAdvanced Malignancies

Start: 2007-05-31Target: 12Updated: 2009-11-19

Phase I Study of Patupilone and RAD001

CompletedNCT00496600

University of Medicine and Dentistry of New JerseyRefractory Malignancy

Start: 2007-07-31End: 2011-02-28Updated: 2012-06-14

Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma

CompletedNCT00715013

University of ZurichRecurrent Glioblastoma Planned for Reoperation

Start: 2008-07-31End: 2010-12-31Updated: 2011-09-15

Phase 2

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

CompletedNCT00219297

Novartis PharmaceuticalsBrain Metastasis, Non-small Cell Lung Cancer

Start: 2005-11-16End: 2010-06-24Updated: 2021-02-21

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

CompletedNCT00273312

Novartis PharmaceuticalsHepatocellular Carcinoma

Start: 2006-01-31Updated: 2017-02-07

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

CompletedNCT00407251

British Columbia Cancer AgencyHormone Refractory Prostate Cancer

Start: 2007-02-28Target: 73Updated: 2010-11-05

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

CompletedNCT00411528

Novartis PharmaceuticalsMetastatic Hormone Refractory Prostate Cancer

Start: 2006-09-30End: 2012-09-30Updated: 2020-12-17